Avecho Biotechnology Limited · ASX:AVE
Avecho Biotechnology — AusBiotech Invest 2025
10 slides from Avecho Biotechnology's conference presentation, Oct 21, 2025
Slide 1: AusBiotech Invest 2025
For personal use only AusBiotech Invest 2025 Developing the first pharmaceutical cannabidiol product for insomnia www.avecho.com.au | ASX:AVE
Slide 2: Management and Board
Management and Board For personal use only Dr Paul Gavin Dr Greg Collier Dr Ross Murdoch Matt McNamara Kathy Connell Chief Executive Officer Chairman Non-Exec Director Non-Exec Director Non-Exec Director An inventor of the TPM Taken drug from CEO of Extractas CIO of Biotech Fund Led ANZ External del
Slide 3: Insomnia is a major problem worldwide
10-30% Insomnia is a major of people across the world For personal use only experience insomnia problem worldwide1 Based on the current Broadly defined as difficulty initiating or global populations up to maintaining sleep 237 million people are affected Insomnia can be a symptom of a range of other
Slide 4: Avecho's TPM increases oral CBD absorption
Avecho’s TPM increases oral CBD absorption For personal use only Cannabidiol (CBD) is the major non-psychoactive Epidiolex® component of medicinal cannabis Avecho’s TPM CBD Only one pharmaceutical CBD product is approved by the FDA (Epidiolex®)1 • Epidiolex was developed by GW Pharma Epidiolex® Oil
Slide 5: Australian TGA Opportunity
Australian TGA Opportunity For personal use only › TGA now allows oral CBD products to be registered as over-the-counter (OTC) medicines1 Ongoing phase 3 Trial › OTC medicines are available from a pharmacist › Largest randomized, placebo-controlled trial in the without a prescription, a significant
Slide 6: Forecast market size
Forecast market size For personal use only It affects 10-30% of the population, with 10- 15% of the population classified as chronic1,2 Globally 9.5M 3.6M people in Australia people in Australia Big Business: Global insomnia market experience symptoms classified as was valued at $US 5.22B in 20244 o
Slide 7: Licensing Deal
Licensing Deal Swiss-based multinational • Sandoz acquired exclusive rights to Avecho’s For personal use only pharmaceutical company spun out of Novartis (Market Cap ~$US 26Bn) pharmaceutical cannabidiol capsule for insomnia in Australia (ROFR ROW) March 20252 • Global presence • Avecho to receive u
Slide 8: Commercial Growth
Europe 20x For personal use only Canada 1.5x Commercial Growth USA 30x China 10x Japan 5x MENA 2x › Commercial validation from multinational LATAM 4x pharmaceutical company Partnered › Australia the first territory in a global strategy US $19M* › Licensing deal marks the first of potentially several
Slide 9: The path ahead
The path ahead Major stackable inflection points For personal use only Significant re-rate anticipated with Pharma deal for Australia Complete positive interim results Phase III Interim Analysis H1 2026 TGA Commercial Launch Phase III Completion 26/27 Discussions Deals for global territories ongoing
Slide 10: Questions Welcome
Questions Welcome For personal use only Dr Paul Gavin Melbourne Office Chief Executive Officer Unit A8, 2A Westall Road T. +61 3 9002 5000 Hallmarc Business Park E. pgavin@avecho.com.au Clayton VIC 3168 Australia T: +61 3 9002 5000 E: info@avecho.com.au